http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2421221-C1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_40564a13f6a73b84e2b8e8c9e15d1e44 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-137 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
filingDate | 2010-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
grantDate | 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d0c4bf6687afe3a7a33db8e489e04928 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1eab5ab97a894f806cc1ed21cee07c6e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1686b450221e23cb11cd4a794a975fea http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b148b709139d3d1aa866f2ee023b7ae |
publicationDate | 2011-06-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | RU-2421221-C1 |
titleOfInvention | Method of treating critical ischemia of lower extremities of various geneses |
abstract | FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to surgery, and concerns treating the patients with critical ischemia of lower extremities of various geneses. That is ensured by a complex background therapy of lower extremities involving intravenous drop introduction of SEROTONIN ADIPINATE 10 mg/day for 10 days with Mexicor added. For the first five days, Mexicor is administered once a day intra-arterially through a femoral catheter on an affected side in a daily dose 800 mg at rate 200 mg/hour. For the following five days, the intravenous drop introduction of Mexicor is performed by the schedule: at 6 o'clock - 200 mg; at 1400 - 300 mg; at 2200 - 300 mg dissolved in physiologic saline 100 ml at introduction rate 200-300 mg/hour. ^ EFFECT: method provides effective treatment and reduced number of failures in the form of amputation of the extremity due to improvement of microcirculation and elimination of reperfusion disorders in ischemic tissues. ^ 2 ex, 4 dwg |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2548739-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2673481-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2553429-C1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2491054-C1 |
priorityDate | 2010-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.